Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C3

Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C3

Olaparib is a potent poly (ADP-ribose) polymerase inhibitor currently used in targeted therapy for treating cancer cells with BRCA mutations. Here we investigate the possible interference of olaparib with daunorubicin (Daun) metabolism, mediated by carbonyl-reducing enzymes (CREs), which play a sign...

Full description

Bibliographic Details
Main Authors:	Tássia S. Tavares, Jakub Hofman, Alžběta Lekešová, Jana Želazková, Vladimír Wsól
Format:	Article
Language:	English
Published:	MDPI AG 2020-10-01
Series:	Cancers
Subjects:	daunorubicin olaparib synergistic anti-proliferative leukaemia KG1α
Online Access:	https://www.mdpi.com/2072-6694/12/11/3127

Similar Items

Intrinsic and extrinsic apoptosis responses in leukaemia cells following daunorubicin treatment
by: Hussain Mubarak Al-Aamri, et al.
Published: (2021-04-01)

Experimental inhibition of proliferative vitreoretinopathy in retinal detachment using daunorubicin
by: Kumar Atul, et al.
Published: (1994-01-01)

Carvedilol Attenuates Inflammatory-Mediated Cardiotoxicity in Daunorubicin-Induced Rats
by: Punniyakoti T. Veeravedu, et al.
Published: (2011-03-01)

Potential effects of pomegranate on lipid peroxidation and pro-inflammatory changes in daunorubicin-induced cardiotoxicity in rats
by: Hayder M Al-Kuraishy, et al.
Published: (2016-01-01)

Profile of olaparib in the treatment of advanced ovarian cancer
by: Chase DM, et al.
Published: (2016-04-01)

Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells
by: Chinnadurai Mani, et al.
Published: (2019-09-01)

Quantitative Characterization of Olaparib in Nanodelivery System and Target Cell Compartments by LC-MS/MS
by: Roberta Ottria, et al.
Published: (2019-03-01)

Nuclear Lipid Microdomains Regulate Daunorubicin Resistance in Hepatoma Cells
by: Michela Codini, et al.
Published: (2018-11-01)

OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer
by: Soupos Nikolaos, et al.
Published: (2015-09-01)

A Pilot Study of Matrix Metalloproteinases on the Model of Daunorubicin-induced Cardiomyopathy in Rabbits
by: Anna Potáčová, et al.
Published: (2007-01-01)

Olaparib nanoparticles potentiated radiosensitization effects on lung cancer
by: Wu M, et al.
Published: (2018-12-01)

The use of PARP inhibitor - olaparib for the treatment of ovarian cancer in clinical practice
by: S V Khokhlova
Published: (2016-12-01)

Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer
by: S V Khokhlova
Published: (2017-09-01)

Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
by: Lalit S Raut
Published: (2015-01-01)

Liposomal daunorubicin and dexamethasone as a treatment for multiple myeloma: the DD Protocol
by: Frederico Luiz Dulley, et al.

Quercetin as a Potential Modulator of P-Glycoprotein Expression and Function in Cells of Human Pancreatic Carcinoma Line Resistant to Daunorubicin
by: Piotr Dziegiel, et al.
Published: (2010-02-01)

Fluorescence spectra of cardiac myosin and in vivo experiment: studies on daunorubicin-induced cardiotoxicity
by: Yang Liu, et al.
Published: (2015-12-01)

Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date
by: Montemorano L, et al.
Published: (2019-12-01)

The combination of olaparib and camptothecin for effective radiosensitization
by: Miura Katsutoshi, et al.
Published: (2012-04-01)

Daunorubicin induced Stevens‐Johnson syndrome: A case report
by: Preeti Shakya, et al.
Published: (2021-07-01)

Different influence of Arac combined with idarubicin and with daunorubicin on malignant molecule expression of acute myelocytic leukemia
by: Abudourexiti Nuerbiya, et al.
Published: (2018-05-01)

ABT-737, Synergistically Enhances Daunorubicin-Mediated Apoptosis in Acute Myeloid Leukemia Cell Lines
by: Hassan Dariushnejad, et al.
Published: (2014-03-01)

The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
by: Hye Jeong Park, et al.
Published: (2018-05-01)

Applications of daunorubicin-loaded PLGA-PLL-PEG-Tf nanoparticles in hematologic malignancies: an in vitro and in vivo evaluation
by: Bao W, et al.
Published: (2019-04-01)

International experience of using olaparib for metastatic castration-resistant prostate cancer: literature review
by: V. B. Matveev, et al.
Published: (2021-02-01)

Response of Estrogen-Receptor-Positive Metastatic Breast Cancer to Olaparib in Late-Line Therapy
by: Toko Kumeta, et al.
Published: (2019-10-01)

Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring BRCA1 Mutation
by: Li X, et al.
Published: (2021-04-01)

Successful olaparib desensitization using a novel one-day protocol
by: Rongbo Zhu, et al.
Published: (2020-11-01)

Troponin-I and left ventricular function in pediatric high-risk acute lymphoblastic leukemia after daunorubicin treatment
by: Rinche Annur, et al.
Published: (2021-03-01)

The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer
by: Liying Ma, et al.
Published: (2020-10-01)

Olaparib in the metastatic HER2-negative breast cancer setting
by: L. G. Zhukova, et al.
Published: (2020-12-01)

Anti-CD123 antibody-modified niosomes for targeted delivery of daunorubicin against acute myeloid leukemia
by: Fu-rong Liu, et al.
Published: (2017-01-01)

The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials
by: Guo XX, et al.
Published: (2018-08-01)

Effect of daunorubicin drug with and without cimetidine on the nucleated cells of bone marrow of balb/c mouse
by: ali asghar Kiani, et al.
Published: (2004-01-01)

Daunorubicin reduces MBNL1 sequestration caused by CUG-repeat expansion and rescues cardiac dysfunctions in a Drosophila model of myotonic dystrophy
by: Mouli Chakraborty, et al.
Published: (2018-04-01)

Treatment with olaparib monotherapy for BRCA2-mutated refractory intrahepatic cholangiocarcinoma: a case report
by: Cheng Y, et al.
Published: (2018-09-01)

VRK1 Depletion Facilitates the Synthetic Lethality of Temozolomide and Olaparib in Glioblastoma Cells
by: Elena Navarro-Carrasco, et al.
Published: (2021-06-01)

Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China
by: Jing Ni, et al.
Published: (2019-11-01)

BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib
by: Niki Karachaliou, MD, PhD, et al.
Published: (2021-03-01)

In vitro cytotoxicity of the LDE: daunorubicin complex in acute myelogenous leukemia blast cells
by: P.E. Dorlhiac-Llacer, et al.
Published: (2001-10-01)